GlobeNewswire by notified

Sabin Vaccine Institute Names Richard Adegbola and Yacine Djibo to Board of Trustees

Share

WASHINGTON, May 25, 2021 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute (Sabin) announced that Professor Richard Adegbola and Yacine Djibo have been elected to the Board of Trustees. Professor Adegbola is a microbiologist, public health advocate and professor in Lagos, Nigeria. Ms. Djibo is founder and executive director of Speak Up Africa, a policy and advocacy action tank promoting public health and development based in Dakar, Senegal.

Sabin will benefit from their global health leadership, as well as their expertise creating community-led solutions to increase vaccine uptake and advance vaccine equity at this critical moment for immunization efforts worldwide, particularly in low- and middle-income countries. The World Health Organization (WHO) estimates that due to COVID-19, vaccination campaigns have been postponed in 50 countries: more than half of the affected countries are in Africa.

“As Sabin continues to meet today’s changing immunization landscape, Richard’s deep background in the lab developing vaccines and, on the ground, delivering them and Yacine’s work developing cross-sector campaigns that spotlight the importance of vaccines and vaccine equity will be invaluable to Sabin and our work to ensure more people globally can get the lifesaving vaccines they need,” said Regina Rabinovich, MD, MPH, chair of the Sabin Board of Trustees.

Professor Adegbola is a research professor at the Nigerian Institute of Medical Research and a consultant for Immunization & Global Health, RAMBICON. His 40-year career has focused on preventing infectious diseases, strengthening health care systems and mentoring young researchers. His dedication to making vaccines more accessible came while working in The Gambia. There, his research contributed to the widespread use of the Haemophilus influenzae type b (Hib) vaccine, which had been the leading cause of meningitis in children. When given routinely, this vaccine now results in a 90 percent decrease in severe Hib infections.

Professor Adegbola’s expertise has also helped shape pneumonia research at Bill & Melinda Gates Foundation and community-led decision making with GlaxoSmithKline. He holds a PhD in medical microbiology and bacteriology from University of Dundee (UK). “With vaccination in low- and middle-income countries, you have to start thinking from day one, how will this be sustainable? You must bring people into the process to take ownership,” he said. “Sabin shares these values and I’m delighted to be joining the board.”

Ms. Djibo founded Speak Up Africa in 2011 to help fill a gap in African voices and leadership contributing to global development policies and the United Nation’s sustainable development goals. Today, the organization works in 10 countries in West and Central Africa driving economic sustainability through bolstering public health. In response to the pandemic, she helped form Stay Safe Africa, a platform for organizations and communities to create tangible actions that build trust around vaccines, as well as a campaign advocating for vaccine equity. Currently, only 0.3 percent of COVID-19 vaccine supply is going to low-income countries.

While pursuing a career in finance, Ms. Djibo’s interest in global health began when she joined the Malaria No More’s Senegal office as its country director. There, she led public and private-sector collaborations to promote malaria treatment and prevention. Ms. Djibo holds a master’s degree in business administration and a bachelor of arts and science in international relations from Boston University. “Community engagement is key to overcoming mistrust and building confidence through actions like using proven channels of communication, engaging trusted messengers with roots in the community and working toward equitable access,” she said. “I’m excited to support programs like Boost, a community dedicated to the needs of immunization professionals, in building capacity sub-nationally and then applying lessons to other places.”

“Richard and Yacine are respected thought leaders, tireless advocates and innovative problem solvers who share our belief that communities and families everywhere must have equal access to the vaccines they need,” commented Amy Finan, Sabin’s chief executive officer.

With the appointment of Professor Adegbola and Ms. Djibo, Sabin’s board consists of 14 members. Learn more at www.sabin.org/board-trustees.

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with more than two decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit https://www.sabin.org and follow us on Twitter, @SabinVaccine.

Media Contact:
Mary Beth Wooden
Vice President, Communications
Sabin Vaccine Institute
+1 (202) 842-5025
press@sabin.org

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Correction to Company announcement – No. 23 / 202419.4.2024 22:20:51 CEST | Press release

Correction to Company announcement – No. 23 / 2024 Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has a correction to company announcement No. 23 /2024, April 19, 2024 - regarding transactions in Zealand’s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons it was reported that member of the management, Henriette Wennicke, was allocated a total of 8,008 restricted stock units with a total value of DKK 9,577,568.00. The correct number was a total of 8,008 restricted stock units with a total value of DKK 4,788,784.00. Please see the attached file(s). # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10

Nokia Corporation: Repurchase of own shares on 19.04.202419.4.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 19 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 19.04.2024 Espoo, Finland – On 19 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL430,8933.30CEUX--BATE--AQEU--TQEX--Total430,8933.30 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of

Landsbankinn hf.: Results of the 2024 AGM of Landsbankinn19.4.2024 20:48:08 CEST | Press release

The annual general meeting (AGM) of Landsbankinn, held on 19 April 2024, agreed to pay a dividend amounting to ISK 16,535 million to shareholders. The dividend is equivalent to 50% of 2023 profits. The dividend will be paid in two instalments, firstly on 24 April 2024 and secondly on 16 October 2024. As a result, total dividend paid by the Bank in 2013-2024 amounts to ISK 191.7 billion. At the AGM, held in Reykjastræti 6, Helga Björk Eiríksdóttir, Chairman of the Board of Directors, delivered the report from the Board for 2023. Lilja Björk Einarsdóttir, CEO, spoke of the Bank’s operation, strategy and activities in the past operating year. The annual financial statement for the past operating year was approved, as was the proposed Remuneration Policy and remuneration to Directors of the Board. The AGM elected the Auditor General (Ríkisendurskoðun) as auditor of Landsbankinn hf. for the 2024 operating year. The Auditor General, in accordance with an authorisation to outsource tasks, and

SKEL fjárfestingafélag hf.: Styrkás finalizes the purchase of Stólpi Gámar ehf. and affiliated companies.19.4.2024 19:20:57 CEST | Press release

Reference is made to the announcement dated 31 January 2024, regarding Styrkás hf., a company 69.64% owned by SKEL fjárfestingafélag hf., signing a purchase agreement to acquire 100% of the shares in six subsidiaries of Máttarstólpi ehf. The purchase agreement was subject to the approval of the Competition Authority. The transaction was finalized today with payment of purchase price and delivering of shares in the following companies: - Stólpi Gámar ehf., id. 460121-1590, Klettagörðum 5, 104 Reykjavík: - Stólpi Smiðja ehf., id. 460121-1750, Klettagörðum 5, 104 Reykjavík; - Klettskjól ehf., id. 460121-0510, Klettagörðum 5, 104 Reykjavík; - Stólpi ehf., 460121-0430, Klettagörðum 5, 104 Reykjavík; - Tjónaþjónustan ehf., id. 460121-1670, Klettagörðum 5, 104 Reykjavík; - Alkul ehf., id. 491020-0830, Haukdælabraut 48, 113 Reykjavík. collectively referred to as "the sold companies". These companies will continue to be operated on a consolidated basis. The Enterprise value of the sold companie

HiddenA line styled icon from Orion Icon Library.Eye